Méndez-Hernández analyzed the serum and tissue samples of primary BC patients in Mexican that received neoadjuvant therapy and confirmed that the polymorphisms of Leptin (LEP rs7799039) and adiponectin (ADIPOQ rs1501299) were risk-contributing factors in overweight/obesity patients (120). This evidence concerns the gene LEP and breast cancer.